Skip to content

8-KAccepted Nov 16, 5:06 PM ET

Aspira Women's Health Inc.: non-reliance on prior 2026 quarterly financial statements

AWHLAspira Women's Health Inc.

Accepted (ET)

5:06 PM

Nov 16, 2026

Filed

Nov 16, 2026

Documents

11

Size

184.9 KB

Summary

Aspira Women's Health Inc.: non-reliance on prior 2026 quarterly financial statements

Updated

What happened

  • On Nov 13, 2026 the audit committee of Aspira Women's Health Inc concluded that the company’s previously issued unaudited Condensed Consolidated Financial Statements for the three and six months ended Mar 31, 2026 and Jun 30, 2026, included in the Form 10-Qs filed May 15, 2026 and Aug 14, 2026, should no longer be relied upon due to material errors in the unaudited Condensed Consolidated Statement of Cash Flows. Management identified errors in the presentation and classification under ASC Topic 230 related to a loan obtained in Jan 2026 and related payments that were reported within operating activities instead of financing activities. The restatement adjustments had no impact on the unaudited Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Operations or total net change in cash, cash equivalents, and restricted cash for the affected periods.

Key details

  • The company plans to restate the unaudited Condensed Consolidated Financial Statements in the Form 10-Qs for the three months ended Mar 31, 2026 and the six months ended Jun 30, 2026. The audit committee has discussed the matters with BDO USA, P.C., the company’s independent registered public accounting firm.
  • For the three months ended Mar 31, 2026 (amounts in thousands): amortization of debt issuance costs $15; other liabilities adjustment $(775); net cash used in operating activities revised from $(359) to $(1,119). Financing: proceeds from Jan 2026 Agile Loan $1,050; principal repayments $(240); payment of debt issuance costs $(50); net cash provided by financing activities revised from $(52) to $708.
  • For the six months ended Jun 30, 2026 (amounts in thousands): amortization of debt issuance costs $37; other liabilities adjustment $(345); net cash used in operating activities revised from $(2,369) to $(2,677). Financing: proceeds from Jan 2026 Agile Loan $1,050; principal repayments $(692); payment of debt issuance costs $(50); net cash provided by financing activities revised from $1,241 to $1,549.
  • Management evaluated disclosure controls and internal control over financial reporting and concluded the matter resulted in a material weakness that will be disclosed in Item 9A of the Form 10-Q/A; the company stated the material weakness will remain until remedial controls operate for a sufficient time and testing shows they are effective.

Why it may matter

  • The filing reports Item 4.02 (non-reliance on previously issued financial statements), which covers the company’s conclusion that certain previously filed quarterly cash flow statements are unreliable and the related internal control weakness. This filing does not show why the insider traded or why the company acted.

AI-written summary · check the filing